Only glucose meters with FDA clearance for use with ALL patients including critically ill
CLIA waived for use with arterial, venous, and capillary samples from critically ill patients
ONLY glucose meter with no known clinical interferences—over 8,000 medications tested
- Measures and corrects for interferences, which cause incorrect glucose results in other meters and patient mismanagement
Proven safety and accuracy
- In one study of over 17,300 capillary results from critically ill patients that were compared to lab results
- In another study of 1,698 arterial and venous results from critically ill patients with over 257 medical conditions were compared to lab results
- Improved accuracy results in less insulin misdosing and better outcomes for critically ill patients
Use of any other meter with critically ill patients is considered off label by the FDA and high complexity testing under CLIA
Use of any other glucose meter with critically ill patients is off label
StatStrip is FDA cleared and CLIA waived for use throughout all hospital and all professional healthcare settings including critical care. Use of any other glucose meter with critically ill patients is considered off-label by the FDA and high complexity testing under CLIA.
The personnel testing requirements for off-label use are very demanding and limit who can perform testing. In addition, a hospital must obtain patient consent to perform off-label testing.
The most extensively studied and proven glucose measurement technology
In addition to the studies submitted to the FDA, 168 other independent studies over the last eight years—including 53 critical care studies—have found no clinically significant interferences for StatStrip. This is a statement that no other glucose meter manufacturer can make. Download a bibliography of publications here
To learn more about how StatStrip can help hospitals avoid the risk of glucose meter off-label use and bring critical care testing to the bedside, call Nova at 800-458-5813, or contact us here